Pfizer's Geodon (ziprasidone HCl) was an effective and generally well-tolerated adjunctive treatment to mood stabilizers for the maintenance treatment of bipolar disorder, according to a new study presented earlier this week at the European Psychiatric Association's European Congress of Psychiatry. Ziprasidone is available in Europe and other markets under the trade name Zeldox.

Pfizer Inc announced the discontinuation of a phase III study of its investigational agent axitinib for the treatment of advanced pancreatic cancer. Based on an interim analysis, an independent Data Safety Monitoring Board (DSMB) found no evidence of improvement in the primary endpoint of survival in patients treated with axitinib and gemcitabine, compared to gemcitabine alone, the current standard of care for patients with advanced pancreatic cancer.

King Pharmaceuticals, Inc reported results from its phase-III 12-month open-label safety and efficacy study evaluating Embeda (morphine sulfate and naltrexone hydrochloride) Extended Release capsules.

The Central Council for Research in Ayurveda and Siddha (CCRAS), the research body under the Department of Ayush to find new inroads on Indian Systems of Medicines (ISM), will soon launch a national research database with comprehensive information on the research in the traditional medicines.